The global inhalation anesthesia market size is expected to reach USD 2.22 billion by 2030, registering a CAGR of 6.65% from 2025 to 2030, according to a new report by Grand View Research, Inc. Inhalation anesthetics offer shorter induction period and recovery time along with better efficacy and lesser adverse effects as compared to other alternatives, thus providing better anesthetic effect during surgical procedures. They also provide excellent control over the duration of anesthesia in the patient. Thus, inhalation anesthesia is being preferred over intravenous anesthesia due to these advantages.
Drugs administered through inhalation anesthesia have a quick onset of action even at low dose as compared to intravenous anesthesia. Using inhalation route for administration helps avoid excessive dosage and keeps the patient’s autonomic functions intact. As these drugs are eliminated via lungs, they have lower chances of accumulation in the body. Hence, they result in lower risk of hepatotoxicity. In addition, drugs administered through inhalation route have limited tolerance and addiction level as compared to other alternatives routes.
With the launch of innovative respiratory products such as AnaConDa (Anaesthetic Conserving Device), administration of inhalation general anesthetic agents such as sevoflurane, isoflurane, & other agents have become easier. Inhalation anesthesia is considered to be the best alternative for patients who are on ventilation for more than 24 hours as it becomes easy to monitor the patient’s health.
Major concern associated with anesthetic gas is that only 5% account for patient use and the rest 95% is released in the atmosphere, which leads to greenhouse effect of these gases. The comparative analysis of sevoflurane, isoflurane, and desflurane based on atmospheric time span and global atmospheric concentrations indicates that desflurane poses a high potential threat for environment.
Request a free sample copy or view report summary: Inhalation Anesthesia Market Report
The sevoflurane segment dominated the market with the largest market share and is expected to grow at a significant CAGR of 7.47% over the forecast period.
In terms of application, the maintenance segment dominated the market with the largest share in 2024 and is the fastest-growing segment and is expected to grow at a CAGR of 6.73% over the forecast period.
The hospital segment dominated the market in 2024 with a share of 68.52% due to various factors such as technological advancements, increasing surgical procedures, and a strong emphasis on patient safety and recovery.
The North America inhalation anesthesia market dominated the global market and accounted for 52.77% of revenue share in 2024, largely driven by an increasing number of surgical procedures, advancements in technology, and a rising elderly population.
The Asia Pacific inhalation anesthesia market is expected to grow at the fastest CAGR over the forecast period, driven by demographic changes, particularly the aging population and increased life expectancy, leading to a higher incidence of chronic diseases that necessitate surgical interventions.
Grand View Research has segmented global inhalation anesthesia market report based on drug, application, end-use, and region:
Inhalation Anesthesia Drug Outlook (Revenue, USD Million, 2018 - 2030)
Sevoflurane
Desflurane
Isoflurane
Others
Inhalation Anesthesia Application Outlook (Revenue, USD Million, 2018 - 2030)
Induction
Maintenance
Inhalation Anesthesia End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Ambulatory Surgical Centers
Others
Inhalation Anesthesia Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Inhalation Anesthesia Market
Halocarbon, LLC
Baxter
AbbVie Inc.
Lunan Pharmaceutical Group
Piramal Enterprises Ltd.
Sandoz Group AG
Fresenius Kabi AG
"The quality of research they have done for us has been excellent..."